Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.
- 1 June 1983
- journal article
- abstracts
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 67 (6), 1174-1177
- https://doi.org/10.1161/01.cir.67.6.1174
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Profiles of prostaglandin metabolites in the human circulation: Identification of late-appearing, long-lived productsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1982
- Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy SubjectsJCI Insight, 1982
- Reduced prostacyclin production in patients with different manifestations of ischemic heart diseaseThe American Journal of Cardiology, 1982
- Inhibition of Prostacyclin and Platelet Thromboxane A2after Low-Dose AspirinThe New England Journal of Medicine, 1981
- Quantitative determination of 6-Oxo-PGF1α in biological fluids by gas chromatography mass spectrometryJournal of Mass Spectrometry, 1980
- 6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects.Hypertension, 1980
- PRODUCTION OF 6-OXO-PGF1α BY HUMAN LUNG IN VIVOThe Lancet, 1979
- A double blind placebo controlled crossover study of prostacyclin in manLife Sciences, 1979
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976
- Thrombokinetics in manJCI Insight, 1969